Eidos Therapeutics

Eidos Therapeutics Initiates ATTRibute-CM, a Phase 3 Study of AG10 in ATTR-CM with Registrational 12-month Endpoint

Eidos Therapeutics, a subsidiary of BridgeBio Pharma, is developing AG10 as a targeted therapeutic for transthyretin amyloidosis. The company's singular mission is…

Subscribe to

Expert and Community Perspectives on Attruby®

In this special session, Dr. Barry Trachtenberg and members of the ATTR amyloidosis community came together to share medical insights and lived experiences related to Attruby™ (acoramidis). This expert-led discussion explores the clinical data, the patient perspective, and what lies ahead for those considering or currently taking Attruby.